Abstract
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Dabigatran - A New Chapter in Anticoagulation
Volume: 10 Issue: 2
Author(s): Shameer Ahmed, Vadim Levin, Robert Malacoff and Matthew W. Martinez
Affiliation:
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Abstract: For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Export Options
About this article
Cite this article as:
Ahmed Shameer, Levin Vadim, Malacoff Robert and W. Martinez Matthew, Dabigatran - A New Chapter in Anticoagulation, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (2) . https://dx.doi.org/10.2174/187152512800388911
DOI https://dx.doi.org/10.2174/187152512800388911 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Precision Displacement Control of a Diamond-shaped Amplifying Mechanism Driven by Piezoelectric Actuator Based on Fuzzy Fractionalorder PIλDμ Controller
Current Nanoscience New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Activation of the Renin-angiotensin System could Cause Hypertension During Fasting in Muslims in the Month of Ramadhan
Current Hypertension Reviews Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies
Current Cancer Therapy Reviews Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine An Educational Altered Eating Intervention’s Effect on Chronic Pain, Satisfaction, and Routine
Applied Clinical Research, Clinical Trials and Regulatory Affairs Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A
Cardiovascular & Hematological Disorders-Drug Targets Novel Function of Beta 2 Glycoprotein I in Angiogenesis
Current Angiogenesis (Discontinued) Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle
Current Pharmaceutical Design Editorial [Hot Topic: Neural Control of the Vasculature: Pharmacological Targets in Vascular Disease (Guest Editors: Andrzej Loesch and Michael R. Dashwood)]
Current Vascular Pharmacology Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations
Current Pharmaceutical Design Endogenous Bufadienolide, Blood Pressure and Alcohol Withdrawal
Current Hypertension Reviews <i>Zingiber officinale</i> Roscoe (Ginger) and its Bioactive Compounds in Diabetes: A Systematic Review of Clinical Studies and Insight of Mechanism of Action
Current Medicinal Chemistry Cardiospecific Troponins as Laboratory Biomarkers of Myocardial Cell Injury in Hypertension: A Mini-Review
Current Medicinal Chemistry Diet and Sudden Death: How to Reduce the Risk
Current Vascular Pharmacology Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities
Current Pharmaceutical Design The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies
Current Alzheimer Research